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CCR5, themajor HIV-1 coreceptor, is a primary target
for HIV-1 entry inhibition strategies. CCL5/RANTES,
a natural CCR5 ligand, is one of the most potent
HIV-1 entry inhibitors and, therefore, an ideal candi-
date to derive HIV-1 blockers. Peptides spanning
the RANTES N-loop/b1-strand region act as specific
CCR5 antagonists, with their hydrophobic N- and
C termini playing a crucial role in virus blockade.
Here, hydrophobic surfaces were enhanced by
tryptophan substitution of aromatic residues, high-
lighting position 27 as a critical hot spot for HIV-1
blockade. In a further molecular evolution step,
C-terminal engraftment of RANTES 400 loop pro-
duced a peptide with the highest solubility and anti-
HIV-1 activity. These modified peptides represent
leads for the development of effective HIV-1 inhibi-
tors and microbicides.
INTRODUCTION
HIV-1 is the causative agent of the acquired immunodeficiency
syndrome (AIDS) pandemic that has relentlessly afflicted several
millions people over the past 3 decades. Despite the massive
research commitment, current therapeutic options cannot erad-
icate the infection and remain financially prohibitive for most
AIDS sufferers worldwide. The urgent need for novel therapeu-
tics, including a long-sought vaccine, effective microbicides,
and new systemic drugs, is therefore a major goal. New classes
of drugs against HIV-1 have recently been developed, including
inhibitors of virus entry into target cells. HIV-1 particles dock to
target cells by interacting, via the envelope protein gp120, with
two receptors, CD4 and a chemokine receptor, either CCR5 or
CXCR4 (Lusso, 2006). Following these initial interactions, which
include profound conformational changes, HIV-1 particles enter
target cells by a gp41-mediated mechanism of virus-cell
membrane fusion (Colman and Lawrence, 2003). Among the
virus-entry inhibitors, T20, a peptide that impedes membrane
fusion by intercalating into and locking gp41 upon its conforma-Chemistry & Biology 19, 1579–158tional change, represents a proof of principle for peptide-based
anti-HIV-1 drugs (Kilby et al., 1998). Other entry inhibitors fall into
the category of HIV-1 coreceptor antagonists. Most important,
CCR5 is a major HIV-1 coreceptor that is almost exclusively
used by HIV-1 strains responsible for initial transmission and
prevalent throughout the asymptomatic phase of the infection
(Lusso, 2006). Therefore, HIV-1 blockade at the CCR5 site repre-
sents an ideal therapeutic route, corroborated by the discovery
that the CCR5 D32 deletion confers HIV-1 infection resistance
(Huang et al., 1996). In order to avoid any proinflammatory
activity, CCR5-targeting HIV-1 blockers should ideally not acti-
vate the receptor; hence, CCR5 antagonism is an important
prerequisite. Maraviroc, a small chemical compound blocking
HIV-1 acting as a CCR5 antagonist, is a successful example in
this class of HIV-1 blockers (Gilliam et al., 2011). An intriguing
alternative to the high-throughput screening of large chemical
compound libraries is represented by the engineering of CCR5
natural chemokine ligands, as they are strong HIV-1 blockers
(Cocchi et al., 1995; Lusso, 2006). Given the extensive knowl-
edge on its structure and its potent anti-HIV-1 activity, CCL5/
RANTES (Regulated upon Activation, Normal T cell Expressed,
and Secreted) represents an ideal molecule to derive CCR5
antagonists with superior HIV-1 blocking capability (Vangelista
et al., 2008). The CCL5/RANTES N terminus has been found to
be the moiety responsible for CCR5 activation (Hartley and Off-
ord, 2005). Several mutants and engineered variants of this
region have been developed with interesting anti-HIV-1 features;
however, most of these RANTES derivatives retained strong
CCR5 agonistic activity (Vangelista et al., 2008). CCL5/RANTES
mutants deprived of CCR5-activating propensity have been
produced, such as C1C5-RANTES, whose anti-HIV-1 activity is
similar to that of the wild-type protein (Polo et al., 2000; Vange-
lista et al., 2010), and 5P12-RANTES, a highly active anti-HIV-1
blocker (Gaertner et al., 2008). In parallel to full-length RANTES
mutagenesis and chemical modification, short peptides have
been derived that encompass the N-loop/b1-strand region of
RANTES, revealing that this moiety accounts for CCR5 binding
in a nonactivating mode (Nardese et al., 2001). Although
RANTES full-length derivatives present higher anti-HIV-1
potency, increasing their potential clinical applicability, peptide
derivatives should bear the advantages of a superior proteolysis
resistance and a lower risk of eliciting a host antibody response.8, December 21, 2012 ª2012 Elsevier Ltd All rights reserved 1579
Figure 1. Tryptophan Scanning at Aromatic Residue Positions
(A) Three-dimensional representation of peptide R2.0, whose aromatic
residues’ side chains are shown, was generated using PyMOL. The NMR
coordinates used were chosen arbitrarily among a large set. In red, the five
original aromatic positions (12, 14, 27, 28, and 29) present in R11-29 and
R1.5G2. N and C, denote N and C termini, respectively. The R2.0 amino acid
sequence has the same color code of the NMR coordinates. Some aromatic
residues, present in R2.0 but not in R11-29, and nonnatural amino acids are
underlined.
(B) Inhibition of HIV-1BaL envelope-mediated fusion by tryptophan-substituted
R1.5G2 peptides. The antiviral activity for each peptide is shown relative to
the IC50 calculated for R1.5G2 (468 nM), whose amino acid sequence is
indicated.
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Enhanced Anti-HIV-1 RANTES-Derived PeptidesIn addition, the prototype peptide R11-29, spanning RANTES
amino acids 11 to 29, has been produced in a retroinverted
version that presented anti-HIV-1 activity similar to R11-29,
disclosing an option for peptide variants with exceptional
resistance to proteolysis (Nardese et al., 2001). R11-29 has
subsequently been investigated by alanine substitution in
hydrophobic regions present at the N and C termini, highlighting
the importance of key hydrophobic residues (Vangelista et al.,
2006). More recently, RANTES N-loop/b1-strand-derived pep-
tides have been rationally designed to improve structuring and
reduce the hydrophilic linker connecting the N- and C-terminal
hydrophobic patches, achieving significant improvement in
antiviral activity (Lusso et al., 2011).
In this report, the anti-HIV-1 activity of RANTES N-loop/b1-
strand peptides has been significantly improved. Tryptophan
substitution of aromatic residues highlighted position 27 as a
hot spot for anti-HIV-1 activity. In addition, according to a
previous mapping of CCL5/RANTES interaction with a CCR5
N-terminal peptide (Duma et al., 2007), a segment correspond-
ing to the 400 loop of the chemokine was added at the peptide
C terminus, improving the resulting peptide’s anti-HIV-1 activity
and solubility. The potency of these new HIV-1 blockers has
been tested in several cellular systems on a panel of R5 HIV-11580 Chemistry & Biology 19, 1579–1588, December 21, 2012 ª2012strains. The rationale for the possible implementation of these
molecularly evolved peptides in the therapy or prevention of
HIV-1 infection is also discussed.
RESULTS AND DISCUSSION
Evolution of RANTES-Derived Peptides: Anti-HIV-1
Activity Enhancement, Structure Stabilization,
and Suitability for Recombinant Expression
The prototype RANTES-derived peptide R11-29 encompasses
the N-loop/b1-strand region of the chemokine, which is involved
in CCR5 docking but is not sufficient for receptor activation
(Nardese et al., 2001). The N- and C-terminal hydrophobic
patches of R11-29 were subsequently shown to be key elements
for the anti-HIV-1 activity (Vangelista et al., 2006). Recently,
R11-29 has been rationally refined through a sequence of steps
that, in envelope-mediated fusion assays, lowered the 50%
inhibitory concentration (IC50) toward HIV-1BaL approximately
30-fold, from 3 mM of R11-29 to 100 nM of peptide R2.0
(Figure 1A) (Lusso et al., 2011). In order to exert their maximal
activity, these peptides need to be covalently dimeric (through
a disulphide bond at the N-terminal C11), N-terminally acety-
lated, and C-terminally amidated. However, given the absence
of detectable R2.0 monomer-monomer interactions by nuclear
magnetic resonance (NMR) (Lusso et al., 2011), peptide struc-
turing appears to occur exclusively within monomers; i.e., not
through the aid of tertiary structure assembly. Hence, monomer
moieties within covalent dimers appear to be relatively free and
independent, a feature that has been further investigated herein.
Efforts to increase anti-HIV-1 activity have been paralleled by
attempts to engineer recombinant RANTES-derived peptides
through: (1) the characterization of peptide monomers; (2) the
elimination of the N-terminal acetylation and the exploration of
alternative amino acids at the N terminus; (3) the conversion of
the C-terminal amidation to a natural carboxyl group; and (4)
the choice of natural instead of nonnatural amino acids. It is
important to note that recombinant expression could allow the
delivery of these peptides as live microbicides, as reported for
full-length RANTES variants (Vangelista et al., 2010). Throughout
their molecular refinement, our RANTES-derived peptides have
been tested against CXCR4-tropic HIV-1 strains, on which they
consistently showed no effect (data not shown).
Expansion of the Hydrophobic Surface by Tryptophan
Substitution of Aromatic Residues
The hydrophobic N and C termini of RANTES N-loop/b1-strand-
derived peptides are crucial for their HIV-1 blocking activity. Of
special importance, alanine replacement or deletion of aromatic
residues resulted in significant activity decrease (Vangelista
et al., 2006). However, substitution of the original residue at
position 28 (a phenylalanine) with 3-(1-naphthyl)-alanine (1Nal)
led to an increase in anti-HIV-1 activity (Lusso et al., 2011).
Therefore, the possibility to improve peptide antiviral activity by
increasing the aromatic volume of hydrophobic residues inspired
the tryptophan scanning procedure described herein. Many
high-affinity protein-protein interactions involve hydrophobic
residues, and often tryptophan is engaged into these interacting
surfaces, supplying its large planar aromatic area to increase
the interaction strength. In these cases, the thermodynamicElsevier Ltd All rights reserved
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Enhanced Anti-HIV-1 RANTES-Derived Peptidescost of exposing a tryptophan residue to the solvent is balanced
by the sequestration of the aromatic side chain from the solvent
upon binding with the protein partner. A strong example of the
aforementioned feature is provided by the high-affinity receptor
for immunoglobulin E (IgE), where several solvent-exposed tryp-
tophan residues are engaged in the binding to IgE (Garman et al.,
2000). At the current stage of knowledge on the CCL5/RANTES-
CCR5 interaction in terms of three-dimensional organization,
antiviral activity improvements could not be assigned with
certainty to a direct peptide interaction with CCR5 moieties.
Thus, successful tryptophan substitutions could also account
for an improvement in the stability of the peptide fold. In the
two cases, the tryptophan involved would be either solvent
exposed or packed within a minihydrophobic core. In a third
possible scenario, a tryptophan residue could interact with the
lipids of the cell membrane, as in the case of the HIV-1 gp41
epitope of the neutralizing monoclonal antibody 4E10 (Sun
et al., 2008). Such tryptophan-lipid interaction could drive a local
peptide enrichment at the cell membrane, facilitating the subse-
quent interaction with CCR5.
In order to investigate the effects of tryptophan substitutions,
we stepped back from R2.0 (Figure 1A), the most active peptide
reported to date, and used R1.5G2 as the optimal scaffold to
test original aromatic positions for improvement. R1.5G2
contains a threonine residue at position 16, a substitution of
the original alanine residue of RANTES, produced to increase
water solubility of the resulting peptide (Lusso et al., 2011),
a convenient feature for the prospected introduction of highly
hydrophobic W residues. Moreover, five aromatic residues are
present in R1.5G2, as in the R11-29 peptide representing
the original CCL5/RANTES sequence. In a series of cell fusion
inhibition assays (Figure 1B), tryptophan substitution of phenylal-
anine at position 12 (R1.5G2W12) led to a marked decrease in
antiviral activity (IC50, 883 nM), while substitution of tyrosine 14
(R1.5G2W14) resulted in an anti-HIV-1 activity identical to that
of the original R1.5G2 peptide (IC50, 468 nM). Substitution of
tyrosine 29 (R1.5G2W29) led to a decrease in anti-HIV-1 activity
(IC50, 616 nM). As expected, however, substitution of phenylala-
nine 28 with tryptophan (R1.5G2W28) led to a significant increase
of antiviral activity (IC50, 207 nM). A favorable increase of hydro-
phobicity/aromatic surface in the amino acid side chain at
position 28 has already been documented with the 1Nal substi-
tution (Lusso et al., 2011), which should exert an effect similar
to that of tryptophan. However, the use of tryptophan instead
of 1Nal would allow a step toward the conversion of peptide
production from the exclusive chemical synthesis to the option
of recombinant expression systems. In search for the optimal
aromatic residue to place at position 28, a tyrosine substitution
was also produced in the R1.5G2 scaffold, leading to a 27–29
YYY motif. It is interesting that Y28 led to a significant increase
in anti-HIV-1 activity (IC50 350 nM; data not shown) with
respect to the original F28 in R1.5G2; however, the Y28 variant
was less efficient in inhibiting HIV-1 as compared to the W28
variant. Remarkably, tryptophan substitution of tyrosine at
position 27 (R1.5G2W27) led to the highest increase in antiviral
activity (IC50,149 nM), a striking result, and a milestone for the
subsequent molecular analysis and evolution of RANTES-based
peptides. In summary, the original aromatic residues in positions
12 and 29 (phenylalanine and tyrosine, respectively) appear toChemistry & Biology 19, 1579–158be the most favorable for the anti-HIV-1 activity of these
peptides, confirming previous data (Vangelista et al., 2006).
Tyrosine in position 14 could be exchanged for tryptophan with
no difference in HIV-1 inhibition; hence, this substitution would
only provide an unnecessary hydrophobicity load, likely resulting
in reduced water solubility of the peptide. Most important, both
peptides in which the original Y27 and F28 were separately
substituted by W led to a substantial increase in antiviral activity.
A recent report on the three-dimensional organization of
CCL5/RANTES oligomers highlighted the 2729 stretch as one
of the regions involved in the oligomerization surface (Wang
et al., 2011). This evidence implies that residues 27–29 could
be recruited for protein-protein interactions. The need for
CCL5/RANTES to be in its monomeric form to efficiently bind
CCR5 (Duma et al., 2007) implies the exposure of the 27–29
hydrophobic/aromatic residue stretch, likely making it available
for CCR5 interaction.
Modifications toward Natural N and C Termini
An initial screening of peptides (based on R1.5G2 as scaffold)
with N-terminal amino acid alternatives to acetylated C11, in
which nonacetylated single residues (M, A, S, T, Y, and W)
preceded C11, did not provide any encouraging result in terms
of HIV-1 inhibitory activity (data not shown). The hydrophobic
or polar amino acids tested were selected in an attempt to
reach a balance between the need for a hydrophobic N-terminal
moiety (important for anti-HIV-1 activity) and a sufficient solu-
bility in water. Despite the failure of this approach, M and Y
N-terminal elongations produced the best antiviral activities.
Some of these peptides (A, M, and W) were also tested in
C-terminally amidated versus carboxylated versions, yielding
similar antiviral activities but higher water solubility when their
C terminus was a natural carboxyl group (data not shown).
In light of this evidence and the results obtained from the
tryptophan scanning of aromatic residues in R1.5G2, attempts
were made to produce potent anti-HIV-1 peptides with a natural
N terminus using the W27 version of R1.5G2 as a scaffold and
the natural carboxyl group at the C terminus. Peptide variants
were synthesized in which the N-terminal acetyl group was
replaced by one to three additional amino acids preceding
C11. According to the results from the initial screening, the
new N termini selected included M and Y as single residues
and combinations of Y- and M-containing double- and triple-
amino-acid stretches. However, the anti-HIV-1 activity of these
N-terminally modified peptides remained well below that of
R1.5G2W27, confirming that the N-terminal acetyl group is
crucial for peptide activity (data not shown). Themost interesting
peptides in terms of antiviral activity and water solubility were
those with Y, SY, and SPM preceding C11. It is interesting that
these new peptides are fully natural and could be expressed
as recombinant molecules. However, as the main focus of this
work was HIV-1 blockade, the subsequent characterization
steps were conducted in the context of N-terminally acetylated
C11 peptides.
W versus 1Nal Comparison at Positions 27 and 28
Given the results obtained with W substitutions at positions
27 and 28 and considering the previously reported enhancement
of activity obtained introducing a 1Nal residue at position8, December 21, 2012 ª2012 Elsevier Ltd All rights reserved 1581
Figure 2. Tryptophan Residues in the b1-Strand Hydrophobic Patch
Are Key for HIV-1 Blockade in CC Chemokine Peptide Scaffolds
(A) Comparison of 1Nal versus W residues in the inhibition of HIV-1BaL enve-
lope-mediated fusion. The antiviral activity for each peptide is shown relative to
the IC50 calculated for R1.5G3 (403 nM). Amino acid sequences are indicated;
1Nal and W residues are underlined.
(B) Comparison of the MIP-1b-derived peptide M12-30PWW (open squares)
with R1.5G2W27-28 (closed squares) for the inhibition of HIV-1BaL envelope-
mediated fusion. Amino acids modified from the original chemokine sequence
are in bold, and dashes indicate a portion of the hydrophilic linker previously
deleted with no loss of anti-HIV-1 activity (Lusso et al., 2011).
(C) Modification of RANTES-derived peptides from R2.0 to R3.0 and their
inhibition of HIV-1BaL envelope-mediated fusion. The antiviral activity for each
peptide is shown relative to the IC50 calculated for R2.0 (104 nM). Amino acid
sequences are indicated, and key residues are underlined.
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tions was compared. A series of peptides was synthesized
including double W and 1Nal at positions 27 and 28 (Figure 2A).
As reported earlier for the W substitution, the 1Nal substitution
of the original Y at position 27 (R1.5G21Nal27) also provided
a significant increase in anti-HIV-1 activity (IC50, 175 nM), as
compared to R1.5G3, which presents the 1Nal in position 28.
The double 1Nal-containing peptide R1.5G31Nal27 (positions
27 and 28) yielded a slight increase in anti-HIV-1 activity (IC50,
305 nM) compared to R1.5G3, yet remaining significantly less
active than R1.5G21Nal27. This discrepancy might be explained
by the possibility that the close proximity of the two bulky
nonnatural naphthyl groups may cause repulsions that in turn
create distortions or instability in the optimal peptide fold1582 Chemistry & Biology 19, 1579–1588, December 21, 2012 ª2012and/or CCR5 interaction conformer. In all cases, the effect
provided by W was superior to that derived from the 1Nal
substitution. This evidence further supported the possibility
to produce these peptides as recombinant molecules. As
expected, the highest anti-HIV-1 activity (IC50, 120 nM) was
exerted by R1.5G2W27–28, the peptide presenting both W27
and W28. Thus, the molecular evolution of these peptides was
advanced keeping W residues at both positions 27 and 28.
Investigating MIP-1b-RANTES Similarities and Hot Spot
Evolution in N-loop/b1-Strand Region Peptides
CCL5/RANTES and CCL4/MIP-1b share common physiological
properties, including the ability to bind CCR5 and block HIV-1
entry, as well as a relatively high sequence similarity; hence,
we compared the anti-HIV-1 activities of N-loop/b1-strand
peptides derived from the two chemokines. MIP-1b is of special
interest since it has been reported to bind solely to CCR5, while
RANTES can bind and activate also CCR1 and CCR3. Therefore,
a human MIP-1b-derived peptide, corresponding to the R11-29
amino acid region (namedM12-30, referring to theMIP-1b amino
acid numbering), was synthesized. A second peptide version,
a M12-30 S14P variant (named M12-30P), and a third, including
the S14P, Y28W and Y29W substitutions (named M12-30PWW),
were also synthesized. In cell fusion inhibition assays, the anti-
HIV-1 activities of M12-30 and M12-30P were comparable to
that of R11-29 (3 mM; data not shown), providing an interesting
general proof of principle for the involvement of the N-loop/b1-
strand in the anti-HIV-1 activity of CCR5-binding chemokines.
Despite the amino acid sequence differences in the N-loop/b1-
strand region of RANTES and MIP-1b, we predicted that the
S14P substitution in M12-30 was likely to provide a structure
stabilization similar to that reported for the A13P substitution in
RANTES-derived peptides (Lusso et al., 2011). Likewise, we
postulated that W substitution for Y28 and Y29 in MIP-1b
(corresponding to Y27 and F28 in RANTES) would confer a higher
antiviral activity. Indeed, M12-30PWW showed a higher HIV-1-
blocking activity (IC50, 1 mM), as compared to both M12-30
and M12-30P. Although the anti-HIV-1 activity enhancement
observed in R1.5G2W27–28 versus R11-29 is by far superior to
that of M12-30PWW versus M12-30, the importance for an
increase in the hydrophobic/aromatic surface in the side chain
of these two positions was confirmed (Figure 2B). Once again,
we confirmed the involvement of residues 27 and 28 (28 and
29 for MIP-1b) in the docking/binding of this group of chemo-
kines to CCR5.
Insertion of W27 and W28 into the R2.0 Scaffold
Next, we switched back to the scaffold of R2.0, the peptide
previously reported to possess the best anti-HIV-1 activity
(Lusso et al., 2011). R2.0 is the result of a thoughtful study
aimed at producing a peptide with a more structured linker
connecting the two N- and C-terminal hydrophobic amino
acid stretches, as compared to the original CCL5/RANTES
sequence. Moreover, R2.0 has a C-terminal ornithine residue
following Y29, an extension that improved significantly the
peptide solubility. Solubility and activity were similar for a
C-terminal carboxylated or carboxyamidated R2.0 (data not
shown). Hence, a natural carboxyl group at the C terminus was
introduced in all the peptides generated from this point onward.Elsevier Ltd All rights reserved
Figure 3. Engraftment of RANTES 400 Loop Enhances Peptides’
Anti-HIV-1 Activity
(A) Peptide regions are highlighted within full-length RANTES three-dimen-
sional structure (PDB coordinates 1HRJ), represented using PyMOL. The
11–29-spanning N-loop/b1-strand is in green, with the two hydrophobic
stretches in yellow, while the 400 loop is in blue. N and C, N and C termini,
respectively.
(B) 400 loop elongation of R1.5G2W27-28 andR3.0 (generating R1.5G2W27-28400
and R4.0, respectively) enhances inhibition of HIV-1BaL envelope-mediated
fusion, shown in relation to the IC50 of R1.5G2W27–28. Peptide sequences
are indicated with the 400 loop underlined.
(C) HIV-1BaL acute infection inhibition by R3.0 (closed squares) and R4.0
(closed circles).
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Enhanced Anti-HIV-1 RANTES-Derived PeptidesPeptide R2.0W27–28 (in which Y27 and 1Nal28 in R2.0 were both
substituted with W residues) exhibited a significantly higher
anti-HIV-1 activity (IC50, 40 nM) than R2.0 (Figure 2C). Moreover,
substitution of the C-terminal R2.0W27-28 ornithine with the
closely related natural amino acid lysine (peptide R3.0) led to
identical solubility and activity (IC50, 40 nM) (Figure 2C), again
pointing toward a possible implementation of these peptides
for their expression in recombinant systems.
C-Terminal Engraftment of the RANTES 400 Loop
Previous mapping studies on CCL5/RANTES residues con-
tributing to the interaction with a sulphated N-terminal CCR5
peptide documented the involvement of the 400 loop region,
suggesting its potential importance in the antiviral activityChemistry & Biology 19, 1579–158(Duma et al., 2007). This region contains a stretch of positively
charged amino acids and is exposed to the solvent. Observing
the three-dimensional structure of RANTES (Figure 3A), we
found that the 400 loop (indicated in blue) protrudes toward
the solvent in a region equidistant from the two hydrophobic
clusters identified within RANTES-derived peptides as the
CCR5-interacting units (indicated in yellow), namely, the
peptide’s termini. Thus, we decided to investigate the impor-
tance of this region for the antiviral activity of our peptides,
as well as its likely beneficial effect on peptide solubility. It is
interesting that a threonine residue is present both at RANTES
positions 30 and 43; hence, this residue was included following
Y29, with amino acids 43–48 (the TRKNRQ stretch encompass-
ing the RANTES 400 loop) engrafted C-terminally into the
peptide. The TRKNRQ stretch was added to R1.5G2W27–28
and R3.0, in order to compare its effects on peptides at different
stage of molecular evolution. Indeed, the resulting peptides,
namely R1.5G2W27–2840
0 and R4.0, displayed superior HIV-1
blocking activity (IC50s, 80 nM and 20 nM, respectively), as
compared to R1.5G2W27–28 and R3.0 (Figure 3B).
The most active peptides, R3.0 and R4.0, were tested also in
experiments of acute HIV-1BaL infection (Figure 3C) in which
they exerted a hierarchical activity (IC50s, 143 nM and 94 nM,
respectively) similar to that observed in the cell fusion inhibition
assays. According to their antiviral activity and sequence
features, subsequent experiments were carried out in parallel
with R3.0 and R4.0.
Monomeric Peptides Reveal a Positive Correlation
between Structural Stability and Antiviral Activity
Predictably, the design of more stable RANTES-derived pep-
tides was accompanied by a parallel increase in anti-HIV-1
activity. Given the fact that previous NMR analysis on disul-
phide-bonded dimeric peptides (R1.5G3 andR2.0) did not reveal
significant tertiary interactions (Lusso et al., 2011), we reasoned
that peptides with high structural stability could exert higher
anti-HIV-1 activity also in their monomeric form, as compared
to peptides of older generation (i.e., less structured). Several
peptides were then analyzed in cell fusion inhibition experiments
in their monomeric form (Figure 4A). Due to the reactive C11 sulf-
hydryl group present in the monomeric peptides, the exclusive
presence of monomers was verified by high-pressure liquid
chromatography (HPLC) under experimental conditions similar
to those of the anti-HIV-1 assays, in order to rule out any activity
interference contributed by the presence of spontaneously
oxidized peptide dimers (data not shown). Indeed, peptide
monomers followed an activity hierarchy identical to that of the
respective dimers, with R3.0, R2.0W27–28, and R4.0 showing
remarkably higher antiviral potencies compared to peptides of
the previous generation (Figure 4A). For each peptide, the gap
in activity was approximately, yet consistently, corresponding
to a 10-fold reduction for the monomer in respect to the dimer.
Similar results were obtained when testing peptide monomers
in acute HIV-1BaL infection experiments (Figure 4B).
The consistent anti-HIV-1 activity increase (directly related to
the increase in stability) observed with monomeric peptides
justified a second attempt in the reshaping of the N terminus to
allow recombinant expression of monomers. According to the
initial results, Y, SY, and SPM residues were added at the8, December 21, 2012 ª2012 Elsevier Ltd All rights reserved 1583
Figure 4. Monomeric Peptides Present an HIV-1 Blocking Hierarchy
Identical to that of Dimeric Counterparts
(A) Comparison of the monomer versus dimer HIV-1BaL envelope-mediated
fusion inhibition for the most relevant peptides.
(B)HIV-1BaLacute infection inhibitionby themonomeric formofR1.5G2W27-2840
0
(closed triangles; IC50, 2.52 mM), R2.0W27–28 (closed rhombi; IC50, 1.77 mM),
R3.0 (closed squares; IC50, 2.06 mM) and R4.0 (closed circles; IC50, 969 nM).
(C) HIV-1BaL envelope-mediated fusion inhibition by dimers of SY-R3.0
(closed squares; IC50, 852 nM), SY-R4.0 (closed circles; IC50, 1.08 mM) and
SY-R1.5G2W27 (open triangles; IC50, 1.06 mM).
(D) HIV-1BaL envelope-mediated fusion inhibition bymonomers of R3.0 (closed
circles), R3.0 C11S (closed squares), SY-R3.0 (open squares), and SY-R3.0
C11S (closed rhombi).
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1584 Chemistry & Biology 19, 1579–1588, December 21, 2012 ª2012N terminus of R4.0 and R3.0, thus eliminating the acetyl group.
When tested in cell fusion inhibition assays, the dimeric versions
of these peptides provided frustrating results, with anti-HIV-1
activities in the same range of the earlier peptide variants con-
taining only the Y27W substitution in the R1.5G2 framework
(Figure 4C). Once again, this likely reflected the importance
of the acetyl group at the N terminus, whose loss appears to
flatten the advantages obtained from the other hot spots. A
C11S substitution variant of SY-R3.0 was also produced, hence
generating solely peptide monomers. It is surprising that the
SY-R3.0 C11S monomer was dramatically less active as HIV-1
inhibitor (IC50, 55 mM) when compared to the SY-R3.0 monomer
version (IC50, 5.5 mM) (Figure 4D). As this result was rather unex-
pected, the C11S variant of R3.0 was also produced (retaining
N-terminal acetylation), in order to exclude any effect due to
the absence of the N-terminal acetyl group. Again, a dramatic
reduction in HIV-1 blocking activity was observed (IC50,
86 mM), confirming the peculiar role played by C11 even in its
free thiol group state. Of note, and according to the reported
three-dimensional organization of CCL5/RANTES oligomers
(Wang et al., 2011), a possible explanation for the C11 effect
might be provided with a reasoning similar to that made earlier
for the 27–29 amino acid stretch. The cysteine 11 residue has
in fact been reported to be involved in the RANTES dimerization
surface and, partially, also in the oligomerization process (Wang
et al., 2011). Hence, C11 not is only involved in a disulphide
bonding with C50 (within full-length RANTES), and in a homodi-
merization disulphide bonding (in the peptides reported herein)
but seems to participate also in the CCL5/RANTES-CCR5
interaction, as evinced from its fundamental importance in the
anti-HIV-1 activity of our RANTES-derived peptides.
Broad Spectrum of HIV-1 Blocking Activity
of RANTES-Derived Peptides
To assess the antiviral activity of our peptides toward primary
viruses that can be encountered in different world regions,
several HIV-1 R5 strains were tested in cell fusion inhibition
experiments using PM1 cells chronically infected with the
different strains as effectors andNIH 3T3 cells expressing human
CD4 and CCR5 as targets. The fusion inhibitor T20 was tested in
parallel for comparison. As expected, R4.0 showed the highest
activity against most strains, and the hierarchy in the peptide
molecular evolution was, overall, respected with R4.0 > R3.0 >
R2.0 (Figure 5A; Lusso et al., 2011). Since several of the strains
tested represent primary CCR5-dependent isolates potentially
involved in viral transmission worldwide, the activity exerted
by our peptides suggests that these could be implemented in
a low-cost microbicide formulation for less developed countries.
RANTES-Derived Peptides Block HIV-1 Infection in
Primary Human CD4+ T Cells and Macrophages
Human CD4+ T cells and macrophages are the major cellular
targets for HIV-1 infection. Hence, R3.0 and R4.0 were tested
in an acute infection assay using HIV-1BaL on human mono-
cyte-derived macrophages established from peripheral blood
mononuclear cells (Figure 5B). The two peptides exerted similar
potency, with IC50s of 194 nM and 167 nM for R3.0 and R4.0,
respectively, confirming their HIV-1 blocking efficiency also on
this important cell target.Elsevier Ltd All rights reserved
Figure 5. R3.0 and R4.0 Inhibit Several R5 HIV-1 Strains, as Well as
HIV-1BaL Macrophage Infection
(A) R5 HIV-1 envelope-mediated fusion inhibition by T20 (white bars), R3.0
(black bars), and R4.0 (gray bars). Several R5 HIV-1 strains have been tested,
including laboratory-adapted (BaL and SF162), primary clade B (QH0692,
Trinidad and Tobago) and C (92BR025, Brazil; 98IN007, India; and 98CN005,
China), and primary pediatric isolates (IT5513, IT5508, IT6088, IT10005, and
IT6366, Italy).
(B) HIV-1BaL acute infection inhibition of human monocyte-derived macro-
phages by R3.0 (closed squares) and R4.0 (closed circles).
Chemistry & Biology
Enhanced Anti-HIV-1 RANTES-Derived PeptidesIn order to test the new generation of RANTES-derived
peptides in a more physiological context, a cell fusion inhibition
assay has been developed in which purified human peripheral
blood CD4+ T lymphocytes were used as target cells, instead
of NIH 3T3 cells. Considering the fact that resting human CD4+
T cells express very low levels of CCR5, T lymphocytes were
preactivated with high doses of interleukin-2 (IL-2; 500 U/ml)
for 1 to 3 weeks, a treatment that is known to upregulate
CCR5 surface expression (Bleul et al., 1997). As this T-cell-
based setup is a novel cell fusion inhibition assay, two experi-
mental variants were implemented to optimize and expand
the potentials of the assay. A first variant (more physiological)
is based on the IL-2-induced endogenous expression of
CCR5, while the second variant takes advantage of the massive
CCR5 expression obtained upon vaccinia virus-encoded exoge-Chemistry & Biology 19, 1579–158nous CCR5. Effector cells were RK13 cells infected with a
HIV-1BaL envelope glycoprotein-expressing vaccinia virus.
R3.0 and R4.0 exerted strong anti-HIV-1 activity in both experi-
mental variants, even though the highest IC50s were obtained
using the endogenous CCR5-based assay (18 nM for R3.0
and 10 nM for R4.0) (Figure 6A). In the vaccinia virus-encoded
exogenous CCR5 assay, the antiviral activity resulted in an
IC50 of 32 nM for R3.0 and 19 nM for R4.0 (Figure 6B).
Given the physiologic conditions of the primary CD4+ T cell-
based assay, the strong activity revealed by these peptides is
very encouraging in the perspective of a potential translation
into therapeutics. In order to confirm the results obtained with
different primary R5 strains (Figure 5A), we selected the clade
C HIV-192BR025 and used chronically infected PM1 cells as
effector cells against IL-2-activated CD4+ T lymphocytes as
target cells; PM1 cells chronically infected by HIV-1BaL were
used as control. This latest variant of the cell fusion inhibition
assay is even more physiological, as it uses blood human
T lymphocytes and a human T-lymphocyte-derived cell line.
Inhibition of the two HIV-1 variants (BaL and 92BR025) by R3.0
and R4.0 was slightly higher than in the original assay using
NIH 3T3 cells, confirming the effectiveness of these peptides
in a physiologically relevant experimental model (Figures 6C
and 6D).
CCR5 Antagonism and Receptor Specificity
of RANTES-Derived Peptides in Chemotaxis Assays
CCR5 activation or antagonism by R3.0 and R4.0 were assessed
using chemotaxis assays. Maraviroc, a well-knownCCR5 antag-
onist was tested in parallel as a control, providing a direct
comparison of two molecularly different CCR5 antagonist cate-
gories, peptides, and small chemical compounds. As illustrated
in Figure 7A, R3.0 and R4.0 showed CCR5 antagonistic activity
comparable to that of Maraviroc, potently blocking lymphocyte
chemotaxis induced by CCL5/RANTES. When tested in the
absence of CCL5/RANTES, neither the RANTES-derived
peptides nor Maraviroc exhibited agonistic activity, as the result-
ing chemotaxis was lower than the basal level of nonstimulated
lymphocytes (Figure 7B). Moreover, earlier peptide variants
effectively blocked RANTES-induced phosphorylation of p38
MAP kinase, demonstrating an antagonistic effect on this
G-protein-independent signaling pathway (Lusso et al., 2011).
Drug resistance remains a major concern in the therapy of
HIV-1 infection. While resistance to Maraviroc has been well
documented, experimental evidence suggests that resistance
to full-length RANTES derivatives as CCR5-directed HIV-1
blockersmay be limited (Nedellec et al., 2010, 2011). This advan-
tage with respect to small chemical compounds is likely to be
provided by the extensive surface of interaction between
CCL5/RANTES and CCR5, a feature that would imply an insur-
mountable fitness cost for the virus in order to maintain CCR5
usage through extensive mutation. The alternative of a switch
to CXCR4 usage appears to be remote, given the emergence
of these strains only at late stages of HIV-1 infection, especially
in prophylactic regimens, and considering the rarity of CXCR4
usage at primary infection. Although RANTES-derived peptides
cannot cover the same extension in terms of CCR5 interaction
surface, they are likely to be more restrictive than Maraviroc in
terms of emergence of resistant strains. Indeed, our attempts8, December 21, 2012 ª2012 Elsevier Ltd All rights reserved 1585
Figure 6. Anti-HIV-1 Activity of R3.0 and
R4.0 Assessed on a Novel Human CD4+
T-Cell-Based Fusion Assay
(A) Antiviral activity of R3.0 (closed squares) and
R4.0 (closed circles) was tested on human CD4+
T cells incubated with RK13 effector cells infected
with a HIV-1BaL envelope glycoprotein-expressing
vaccinia virus.
(B) Experimental setup as in (A), with the additional
infection of CD4+ T cells with a vaccinia virus en-
coding for CCR5.
(C) Experimental setup as in (A), replacing RK13
cells with HIV-1BaL chronically infected PM1 cells.
The IC50s for R3.0 and R4.0 were 66 nM and
25 nM, respectively.
(D) Experimental setup as in (C), using HIV-
192BR025 chronically infected PM1 cells. The IC50s
for R3.0 and R4.0 were 662 nM and 653 nM,
respectively.
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peptide versions failed to produce HIV-1 strains that could be
grown in the long term (data not shown).
Overall, the molecular evolution of RANTES-derived peptides
reported herein, culminating in the generation of R3.0 and R4.0,
has yielded promising new inhibitors with remarkable anti-HIV-1
and CCR5 antagonistic activities. Of note, a system has been
successfully engineered to produce recombinant N-terminally
acetylated proteins in E. coli (Johnson et al., 2010), opening an
option for the expression of R3.0 and R4.0. These last-genera-
tion RANTES-derived peptides display a pharmacological
potency comparable to that of Maraviroc, an anti-HIV-1 drug
currently used in therapeutic regimens, and therefore represent
new leads for the development of effective systemic or topical
HIV-1 inhibitors.
SIGNIFICANCE
Efforts have been made to develop peptides originally
derived from the N-loop/b1-strand region of human CCL5/
RANTES that exert potent anti-HIV-1 activity. At present,
very little is known about the structural details by which
CCL5/RANTES and HIV-1 gp120 bind to CCR5 and interfere
with each other. A significant advantage of peptides over
full-length RANTES lies in their capability to block HIV-1 by
binding to CCR5 as antagonists, i.e., in the absence of
receptor activation. Clearly, the identification of the molec-
ular portion that RANTES uses to interact with CCR5 and
directly interfere with gp120 disclosed the possibility to
enhance and evolve peptides as small folded units with
safe anti-HIV-1 activity. These peptides also represent an
ideal scaffold to investigate in more detail structural
information on CCL5/RANTES-CCR5 binding, as well as
computer-aided drug design. In addition, their relatively
small size may be advantageous, as they could provide
a better biodistribution and be less immunogenic. In this1586 Chemistry & Biology 19, 1579–1588, December 21, 2012 ª2012 Elsevier Ltd All rights rereport, RANTES-derived peptides
have been generated that brought a
significant improvement in antiviralactivity and evolved toward their suitability for the expres-
sion in recombinant systems. R3.0 and R4.0 are the most
potent peptides developed and present IC50 values that
closely match that of T20, an HIV-1 blocking peptide
currently used in therapy. They also present pharmacolog-
ical features that resemble those of Maraviroc, an anti-
HIV-1 drug acting as CCR5 antagonist. Given the strong
need for an efficacious prevention of the emergence of
millions of new AIDS cases each year, RANTES-derived
peptides represent an interesting option for their imple-
mentation in the form of topical microbicides.
EXPERIMENTAL PROCEDURES
Peptide Synthesis
Peptides were synthesized by standard solid-phase protocols using Fmoc
chemistry and purified by reverse-phase HPLC (RP-HPLC) to >95% purity.
Peptides were dimerized by oxidation of the N-terminal cysteine residues
and N-terminally acetylated. Some of the peptides were C-terminally ami-
dated. For stable dimerization, peptides were incubated overnight in 50%
dimethyl sulfoxide (DMSO) (Sigma) in water; DMSO was removed by freeze
drying, and the dimerized peptides were purified by RP-HPLC. The purity of
the final stock was >97%; the Ellman test for free sulfhydryl groups was
negative. For simplicity, amino acid residues in each peptide were numbered
as in the full-length RANTES molecule.
HIV-1 Env-Mediated Cell Fusion Assay
Antiviral activity was evaluated using two assays: an HIV-1 envelope-mediated
cell fusion assay and an acute HIV-1 infection assay, both based on the proto-
type CCR5-dependent (R5) isolate, HIV-1BaL. The cell fusion assay was per-
formed using a modification of the test (Nardese et al., 2001), based on
a vaccinia virus technology, originally developed by Berger and coworkers
(Nussbaum et al., 1994). In the modified assay, the effector cells were chron-
ically infected PM1 cells (Lusso et al., 1995), whereas the target cells were NIH
3T3 mouse fibroblast cells stably expressing human CCR5 and human CD4.
Sixteen hours before the test, effector cells were infected with a vaccinia
vector expressing bacteriophage T7 RNA polymerase, while target cells
were infected with a vaccinia vector expressing the LacZ reporter gene under
the control of the T7 promoter, as described elsewhere (Nussbaum et al.,
1994). All vaccinia virus infections were performed in Dulbecco’s modifiedserved
Figure 7. R3.0, R4.0 and Maraviroc Exert Similar Antichemotactic
Activities
(A) Inhibition of RANTES-induced human lymphocyte chemotaxis by pre-
incubation with R3.0, R4.0, or Maraviroc. CCR5-mediated chemotaxis is
indicated as percentage of lymphocyte migration induced by RANTES. Basal
chemotaxis of nonstimulated lymphocytes was set as 0.
(B) R3.0, R4.0, and Maraviroc CCR5 antagonism is assessed by the absence
of lymphocyte migration. Chemotaxis is reported as percentage of non-
stimulated lymphocyte migration (Basal).
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The cells were then washed with DMEM 2.5%, and the effector cells were
mixed for 2 hr with the target cells in the presence or absence of the inhibitors.
Cell fusion was determined by measurement of b-galactosidase activity in
nonionic detergent cell lysates as described (Nussbaum et al., 1994).
In addition to the assay described earlier, a second modified cell fusion inhi-
bition assaywas used. In this assay, primary CD4+ T lymphocytes purified from
human peripheral blood mononuclear cells (PBMC) were used as target cells
instead of NIH 3T3 cells, and RK13 cells infected with a HIV-1BaL envelope
glycoprotein-expressing vaccinia virus were used as effector cells instead of
PM1 cells. Briefly, PBMC were isolated by Lympholyte Cell Separation Media
(Cedarlane Laboratories Limited) gradient centrifugation of buffy coat pre-
parations from healthy blood donors. Subsequently, PBMC were stimulated
with 500 U/ml recombinant human IL-2 (Chiron) in complete RPMI medium
for 7 to 21 days to induce surface expression of CCR5. The day before the
cell fusion inhibition assay, CD4+ T cells were purified from PBMC by negative
selection using Dynabeads goat antimouse immunoglobulin G (Dynal) and
a cocktail of purified monoclonal antibodies against human CD19, CD16,
CD56, CD8 (AL-Immunotools), and CD14 (Serotech). CD4+ T cells were then
infected with the vaccinia vector expressing the LacZ reporter gene under
the control of T7 promoter. In a set of experiments, CD4+ T cells were infected
also with a vaccinia vector encoding for human CCR5. Infection was carried
out in DMEM in the absence of FBS during the first 2 hours, then the cells
were diluted using DMEM supplemented with 2.5% FBS. In parallel, RK13
effector cells were infected with a vaccinia vector expressing bacteriophageChemistry & Biology 19, 1579–158T7 RNA polymerase. The following day, CD4+ T cells (target) were incubated
with effector cells 4 hr in the absence or presence of inhibitors. After incuba-
tion, cells were lysed and cell fusion was determined as described earlier.
As an alternative to RK13 cells, PM1 cells chronically infected with HIV-1BaL
and, in separate experiments, a primary R5 isolate of clade C (HIV-192BR025)
were also used as effector cells.
HIV-1 Infection Assay
Acute HIV-1 infection was obtained by adding HIV-1BaL stocks (50 median
tissue-culture-infective doses [TCID50] per well) to PM1 cells (2 3 10
4 per
well) in complete RPMI medium. Experiments were performed in triplicate
using 96-well round-bottom microtiter plates in the presence or absence of
inhibitors. After incubation at 37C for 16 hr, the wells were washed twice,
and complete medium, with or without the inhibitors, was added. After
48 hr, 75% of the supernatant was removed for the HIV-1 p24 antigen
measurement and replaced by an equal volume of medium containing the
inhibitors. Virus replication was assayed at Day 4 postinfection by the p24
antigen ELISA. Supernatants were diluted in 1% Empigen BB detergent
(Calbiochem) to disrupt virions and added to a 96-well ELISA plate coated
with anti-HIV-1 p24 polyclonal antibodies (Aalto Bio Reagents Ltd.) and
incubated 2 hr at room temperature. The plate was then washed three times
in Tris-buffered saline (1.5 M NaCl, 250 mM Tris, pH 7.5) and an alkaline phos-
phatase-conjugated anti-HIV-1 p24 monoclonal antibody (Aalto Bio Reagents
Ltd.) was added for 1 hr at room temperature. After washing three times
with TROPIX buffer (10 mM MgCl2, 200 mM Tris, pH 9.8), p24 was detected
adding the luminescence substrate CSPD TROPIX (Applied Biosystems),
and the signal was analyzed using a Mithras LB 940 luminometer (Berthold
Technologies). Levels of p24 were calculated generating a standard curve
with HIV-1 p24 antigen standards.
Human monocyte cultures were established from PBMC isolated from
Ficoll-Hypaque (Pharmacia) density gradient centrifugation of buffy coat
preparations obtained from healthy HIV-1 seronegative blood donors. PBMC
(83 106/ml) were cultured in DMEM supplemented with 5% AB serum (Lonza
BioWhittaker), 10% fetal calf serum (FCS), 2 mM glutamine, 50 mg/ml strepto-
mycin, and 100 U/ml penicillin (Lonza BioWhittaker), and monocytes were
allowed to adhere in T75 flasks for 2 hr at 37C. Nonadherent cells were then
removed by washing with medium. After 24 hr, adherent cells were
recovered, seeded (1 3 105 per well) in 96-well flat-bottom plates in DMEM
supplemented with 10% FCS and 5% AB serum, and allowed to differentiate
into monocyte-derived macrophages (MDM) 7–10 days before infection.
MDMwere infected in quadruplicatewithHIV-1BaL (50 TCID50 perwell) in a total
volume of 0.2 ml in the presence or absence of inhibitors. After overnight
incubation, unbound virus was removed by extensive washing, fresh medium
was added, and cultures were further incubated at 37C. Supernatants were
harvested at Day 4 for p24 antigen determination as described earlier.
Lymphocyte Chemotaxis Assay
PM1 is a unique CD4+ CCR5+ human T cell clone susceptible to a wide variety
of primary HIV-1 isolates, including those exclusively using CCR5 as corecep-
tor (Lusso et al., 1995); thus, it was used for the chemotaxis assays in consis-
tency with the antiviral assays. The chemotactic activity was assayed in
duplicate 24-well Transwell chambers (pore size, 5 mm; Costar) as previously
described (Lusso et al., 2011). To test agonistic activity, RANTES, RANTES-
derived peptides, or Maraviroc were diluted in 600 ml RPMI containing 0.5%
human serum albumin and added to the lower chamber; a total of 2 3 105
PM1 cells in 100 ml RPMI were added to the upper chamber. To test antago-
nistic activity, the peptides or Maraviroc were mixed with the cells prior to
addition to the upper chamber. The number of cells migrated into the lower
chamber in replicate wells was measured using a Gallios flow cytometer
(Beckman Coulter). Specific cell migration was calculated by subtracting the
number of cells migrated in the absence of the chemotactic factor (basal
chemotaxis) from the number of cells migrated in the presence of the chemo-
tactic factor; chemotaxis inhibition by RANTES peptides was calculated as the
percentage of cells migrated toward RANTES in the absence of the peptide.
Statistical Analysis
Dose-response curves were fitted using GraphPad Prism version 5.04
(GraphPad Software) in order to calculate IC50 concentrations through8, December 21, 2012 ª2012 Elsevier Ltd All rights reserved 1587
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Enhanced Anti-HIV-1 RANTES-Derived Peptidesnonlinear regression analysis. All data are expressed as the means ± SD for
two independent experiments performed in triplicate.
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